16.0 Abstract: Hormone Responsive Cancers Program The overarching goal of the Hormone Responsive Cancers (HRC) Program of UMGCC is to reduce morbidity and mortality from cancers of hormone-responsive tissues. To achieve this mission, the program focuses on three specific themes and related aims: Theme 1: Therapeutic strategies against hormone-responsive tumors?identify new agents to target malignancies that remain responsive to hormone manipulation; Theme 2: Mechanisms of innate and acquired hormone resistance?identify and target the mechanisms that confer de novo or acquired resistance to hormone manipulation; and Theme 3: Invasion and metastasis? identify the mechanisms that promote tumor dissemination and identify therapeutic strategies to target these mechanisms. The HRC Program has 47 members representing 16 academic departments and 5 schools/colleges of the University of Maryland. Members of the program conduct cancer-focused research that receives $7.1 million total annual funding, including $3.4 million from NCI and $2.6 million from other peer-reviewed sources. In addition, HRC Program members receive over $1 million annually from non-peer-reviewed funding sources. Between January 2010 and December 2014, HRC members authored 407 cancer-related publications, of which 30 percent resulted from intraprogrammatic and 23 percent from interprogrammatic collaborations. Twenty-two percent of the publications represent collaborations with external investigators. Research efforts of HRC faculty are supported by extensive use of the BSS, FCSS, GSS, ISS, PBSS, and TLSS.
Showing the most recent 10 out of 257 publications
